Table 1.
Summary of Targeted Therapies for the Treatment of Psoriasis Vulgaris
| Drug Class | Agent | Target(s) | Stage of Development in Psoriasis | Administration | NCT Identifier |
|---|---|---|---|---|---|
| TNFα inhibitors | Adalimumab | TNFα | Approved | Sc | |
| Certolizumab | TNFα | Approved | Sc | ||
| Etanercept | TNFα | Approved | Sc | ||
| Infliximab | TNFα | Approved | Iv | ||
| Golimumab | TNFα | Sc | |||
| IL-17 inhibitors | Brodalumab | IL-17RA | Approved | Sc | |
| Ixekizumab | IL-17A | Approved | Sc | ||
| Secukinumab | IL-17A | Approved | Sc | ||
| Bimekizumab | IL-17A, IL-17F | Phase 3 | Sc | NCT03412747, NCT03536884, NCT03598790, NCT03766685 | |
| Netakimab (BCD-085) | IL-17A | Phase 3 (approved in Russia) | Sc | NCT03390101 | |
| ABY-035 | IL-17A, albumin | Phase 2 | Sc | NCT03591887 | |
| Sonelokinab (M1095) | IL-17A, IL-17F | Phase 2 | Sc | NCT03384745 | |
| Vunakizumab (SHR-1314) | IL-17A | Phase 3 | Sc | NCT04839016 | |
| IL-23 inhibitors | Guselkumab | IL 23p19 | Approved | Sc | |
| Risankizumab | IL 23p19 | Approved | Sc | ||
| Tildrakizumab | IL 23p19 | Approved | Sc | ||
| Mirikizumab | IL-23p19 | Phase 3 | Sc | NCT03482011, NCT03535194, NCT03556202 | |
| IL-12/23 inhibitor | Ustekinumab | IL-12/23p40 | Approved | Sc | |
| PDE4 inhibitors | Apremilast | PDE 4 | Approved | Oral | |
| Roflumilast | PDE 4 | Phase 3 | Topical/oral | NCT04549870, NCT04211363, NCT04211389, NCT04286607 | |
| Crisaborole (AN2728) | PDE 4 | Phase 2 | Topical | NCT01300052 | |
| Hemay005 | PDE 4 | Phase 2 | Oral | NCT04102241 | |
| JAK inhibitors | Deucravacitinib (BMS-986165) | TYK2 | Phase 3 | Oral | NCT04036435, NCT04772079, NCT03924427, NCT04167462, NCT03611751, NCT03624127 |
| Tofacitinib (CP-690,550) | JAK1, JAK3 | Phase 3 | Oral | ||
| Abrocitinib (PF-04965842) | JAK1 | Phase 2 | Oral | NCT02201524 | |
| Baricitinib (INCB028050) | JAK1, JAK2 | Phase 2 | Oral | NCT01490632 | |
| Brepocitinib (PF-06700841) | JAK1, TYK2 | Phase 2 | Oral/topical | NCT02969018, NCT03850483 | |
| Itacitinib (INCB039110) | JAK1 | Phase 2 | Oral | NCT01634087 | |
| Peficitinib (ASP015K) | JAK1, JAK2 JAK3, TYK2. | Phase 2 | Oral | NCT01096862 | |
| PF-06826647 | TYK2 | Phase 2 | Oral | NCT03895372 | |
| Ruxolitinib | JAK1, JAK2 | Phase 2 | Topical | NCT00617994 | |
| Solcitinib (GSK2586184) | JAK1 | Phase 2 | Oral | NCT01782664 | |
| RORγt inhibitor | AUR101 | RORγt | Phase 2 | Oral | NCT04207801 |
| BI 730357 | RORγt | Phase 2 | Oral | NCT03635099, NCT03835481 | |
| ESR-114 | RORγt | Phase 2 | Topical | NCT03630939 | |
| GSK-2981278 | RORγt | Phase 2 | Topical | NCT03004846 | |
| JTE-451 | RORγt | Phase 2 | Oral | NCT03832738 | |
| VTP-43742 | RORγt | Phase 2 | Oral | NCT02555709 | |
| STAT inhibitor | STA-21 | STAT3 | Phase 2 | Topical | NCT01047943 |
| S1PR1 antagonist | Ponesimod (ACT-128800) | S1PR1 | Phase 2 | Oral | NCT00852670, NCT01208090 |
| A3AR agonist | Piclidenoson (CF101) | A3AR | Phase 3 | Oral | NCT03168256 |
| AhR agonist | Tapinarof | AhR | Phase 3 | Topical | NCT04053387 |
| Fumeric acid esters | Fumaderm | Multiple | Approved in Germany | Oral | |
| Skilarence | Multiple | Approved in Europe | Oral | ||
| LAS41008 | Multiple | Phase 3 | Oral | NCT01726933 | |
| FP-187 | Multiple | Phase 2 | Oral | NCT01230138 | |
| PPC-06 | Multiple | Phase 2 | Oral | NCT03421197 | |
| XP23829 | Multiple | Phase 2 | Oral | NCT02173301 | |
| ROCK-2 inhibitor | Belumosudil (KD025) | ROCK2 | Phase 2 | Oral | NCT02317627, NCT02106195, NCT02852967 |
| HSP90 inhibitor | RGRN-305 (CUDC- 305) | HSP90 | Phase 1 | Oral | NCT03675542 |
Abbreviations: A3AR, A3 adenosine receptor; AhR, aryl hydrocarbon receptor; HSP90, heat shock protein 90; Iv, intravenous; JAK, janus kinase; PDE4, phosphodiesterase 4; ROCK, Rho-associated kinase; RORγt, retinoic acid-related orphan nuclear receptor gamma; Sc, subcutaneous.